1. Home
  2. AEYE vs MOLN Comparison

AEYE vs MOLN Comparison

Compare AEYE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioEye Inc.

AEYE

AudioEye Inc.

HOLD

Current Price

$12.30

Market Cap

170.9M

Sector

Technology

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.12

Market Cap

157.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AEYE
MOLN
Founded
2005
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
170.9M
157.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AEYE
MOLN
Price
$12.30
$4.12
Analyst Decision
Strong Buy
Hold
Analyst Count
3
1
Target Price
$22.00
$4.00
AVG Volume (30 Days)
109.5K
10.9K
Earning Date
11-04-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$39,540,000.00
N/A
Revenue This Year
$17.16
N/A
Revenue Next Year
$14.79
$1,000.00
P/E Ratio
N/A
N/A
Revenue Growth
18.57
N/A
52 Week Low
$8.91
$3.36
52 Week High
$28.50
$5.99

Technical Indicators

Market Signals
Indicator
AEYE
MOLN
Relative Strength Index (RSI) 44.56 52.30
Support Level $11.04 $3.99
Resistance Level $12.92 $4.11
Average True Range (ATR) 0.73 0.26
MACD 0.01 -0.03
Stochastic Oscillator 43.88 28.59

Price Performance

Historical Comparison
AEYE
MOLN

About AEYE AudioEye Inc.

AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: